abstract |
This invention is directed to quinoline/quinoxaline compounds which inhibit platelet-derived growth factor or p56<lck> tyrosine kinase activity, to pharmaceutical compositions comprising these compounds, and to the use of these compounds for treating a patient suffering from or subject to disorders/conditions involving cellular differentiation, proliferation, extracellular matrix production or mediator release and/or T cell activation and proliferation. |